Exforge and Coordination abnormal - a phase IV clinical study of FDA data

Summary:

Coordination abnormal is reported as a side effect among people who take Exforge (amlodipine besylate; valsartan), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Coordination abnormal when taking Exforge. It is created by eHealthMe based on reports of 12,942 people who have side effects when taking Exforge from the FDA, and is updated regularly.

What is Exforge?

Exforge has active ingredients of amlodipine besylate; valsartan. It is often used in high blood pressure. eHealthMe is studying from 13,350 Exforge users. Check the latest studies of Exforge.

What is Coordination abnormal?

Coordination abnormal (abnormal movement) is found to be associated with 989 drugs and 1,215 conditions by eHealthMe. Check the latest studies of Coordination abnormal.

On Feb, 17, 2026

12,942 people reported to have side effects when taking Exforge.
Among them, 16 people (0.12%) have Coordination abnormal.

Could Exforge cause Coordination abnormal?

Among these 16 people:

How long have people been on Exforge when they have Coordination abnormal? *

What is the gender of people who have Coordination abnormal when taking Exforge? *

female: 56.25 %
male: 43.75 %

What is the age of people who have Coordination abnormal when taking Exforge? *

What are other drugs people take besides Exforge? *

What are other side effects people have besides Coordination abnormal? *

Weakness: 12 people, 75.00%
Fall: 10 people, 62.50%
Memory Loss: 7 people, 43.75%
Dizziness: 7 people, 43.75%
Feeling Abnormal: 7 people, 43.75%
Wound: 6 people, 37.50%
Nervousness: 6 people, 37.50%
Limb Discomfort (discomfort in leg): 6 people, 37.50%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 37.50%
Metatarsalgia (injury described as pain in the forefoot that is associated with increased stress): 6 people, 37.50%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 37.50%
Stable Angina (a constant chest pain): 3 people, 18.75%
Sinusitis (inflammation of sinus): 3 people, 18.75%
Type 2 Diabetes: 1 person, 6.25%
Malignant Ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen): 1 person, 6.25%
High Blood Cholesterol: 1 person, 6.25%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 6.25%
Gastrointestinal Carcinoma (cancer of stomach or intestine): 1 person, 6.25%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 6.25%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Exforge and have Coordination abnormal?

- Check whether Coordination abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Exforge:

Exforge (13,350 reports)

Coordination abnormal treatments and more:

Coordination abnormal (17,007 reports)

How severe was Coordination abnormal and when was it recovered:

Coordination abnormal in Exforge

Expand to all the drugs that have ingredients of amlodipine besylate; valsartan:

Coordination abnormal and drugs with ingredients of amlodipine besylate; valsartan (16 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Exforge:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Coordination abnormal:

Coordination abnormal (989 drugs)

Browse all the conditions that are associated with Coordination abnormal:

Coordination abnormal (1,215 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on amlodipine besylate; valsartan (the active ingredients of Exforge) and Exforge (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.